

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/656,093B
Source: IFWC
Date Processed by STIC: 4/14/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 703-308-4212; FAX: 703-308-4221

Effective 12/13/03: TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm>


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to (EFFECTIVE 12/01/03):
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 4B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/03



IFWO

RAW SEQUENCE LISTING

DATE: 04/14/2004

PATENT APPLICATION: US/10/656,093B

TIME: 14:39:47

Input Set : A:\256-152div corrected in response to notice to comply.txt

Output Set: N:\CRF4\04142004\J656093B.raw

3 <110> APPLICANT: YOUNG, ANDREW A.
 4 VINE, WILL
 5 BEELEY, NIGEL R.A.
 6 PRICKETT, KATHRYN S.
 8 <120> TITLE OF INVENTION: INOTROPIC AND DIURETIC EFFECTS OF GLP-1 AND GLP-1 AGONISTS
 10 <130> FILE REFERENCE: 256-152DIV US
 12 <140> CURRENT APPLICATION NUMBER: 10/656,093B
 13 <141> CURRENT FILING DATE: 2003-09-05
 15 <160> NUMBER OF SEQ ID NOS: 75
 17 <170> SOFTWARE: PatentIn Ver. 2.1
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 39
 21 <212> TYPE: PRT
 22 <213> ORGANISM: Heloderma horridum
 24 <220> FEATURE:
 25 <223> OTHER INFORMATION: Exendin-3
 27 <400> SEQUENCE: 1
 28 His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
 29 1 5 10 15
 31 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
 32 20 25 30
 34 Ser Gly Ala Pro Pro Pro Ser
 35 35
 38 <210> SEQ ID NO: 2
 39 <211> LENGTH: 39
 40 <212> TYPE: PRT
 41 <213> ORGANISM: Heloderma suspectum
 43 <220> FEATURE:
 44 <223> OTHER INFORMATION: Exendin-4
 46 <400> SEQUENCE: 2
 47 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
 48 1 5 10 15
 50 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
 51 20 25 30
 53 Ser Gly Ala Pro Pro Pro Ser
 54 35
 57 <210> SEQ ID NO: 3
 58 <211> LENGTH: 30
 59 <212> TYPE: PRT
 60 <213> ORGANISM: Homo sapiens
 62 <220> FEATURE:
 63 <223> OTHER INFORMATION: GLP-1
 65 <400> SEQUENCE: 3

pg 4,6

RAW SEQUENCE LISTING

DATE: 04/14/2004

PATENT APPLICATION: US/10/656,093B

TIME: 14:39:47

Input Set : A:\256-152div corrected in response to notice to comply.txt

Output Set: N:\CRF4\04142004\J656093B.raw

```

66 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
67   1           5           10           15
69 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
70           20           25           30
73 <210> SEQ ID NO: 4
74 <211> LENGTH: 39
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: Description of Artificial Sequence: Exendin or
80   exendin agonist
82 <220> FEATURE:
83 <221> NAME/KEY: MOD_RES
84 <222> LOCATION: (1)
85 <223> OTHER INFORMATION: His, Arg or Tyr
87 <220> FEATURE:
88 <221> NAME/KEY: MOD_RES
89 <222> LOCATION: (2)
90 <223> OTHER INFORMATION: Ser, Gly, Ala or Thr
92 <220> FEATURE:
93 <221> NAME/KEY: MOD_RES
94 <222> LOCATION: (3)
95 <223> OTHER INFORMATION: Asp or Glu
97 <220> FEATURE:
98 <221> NAME/KEY: MOD_RES
99 <222> LOCATION: (5)
100 <223> OTHER INFORMATION: Ala or Thr
102 <220> FEATURE:
103 <221> NAME/KEY: MOD_RES
104 <222> LOCATION: (6)
105 <223> OTHER INFORMATION: Ala, Phe, Tyr or naphthylalanine
107 <220> FEATURE:
108 <221> NAME/KEY: MOD_RES
109 <222> LOCATION: (7)
110 <223> OTHER INFORMATION: Thr or Ser
112 <220> FEATURE:
113 <221> NAME/KEY: MOD_RES
114 <222> LOCATION: (8)
115 <223> OTHER INFORMATION: Ala, Ser or Thr
117 <220> FEATURE:
118 <221> NAME/KEY: MOD_RES
119 <222> LOCATION: (9)
120 <223> OTHER INFORMATION: Asp or Glu
122 <220> FEATURE:
123 <221> NAME/KEY: MOD_RES
124 <222> LOCATION: (10)
125 <223> OTHER INFORMATION: Ala, Leu, Ile, Val, pentylglycine or Met
127 <220> FEATURE:
128 <221> NAME/KEY: MOD_RES

```

RAW SEQUENCE LISTING

DATE: 04/14/2004

PATENT APPLICATION: US/10/656,093B

TIME: 14:39:47

Input Set : A:\256-152div corrected in response to notice to comply.txt

Output Set: N:\CRF4\04142004\J656093B.raw

129 <222> LOCATION: (11)
130 <223> OTHER INFORMATION: Ala or Ser
132 <220> FEATURE:
133 <221> NAME/KEY: MOD_RES
134 <222> LOCATION: (12)
135 <223> OTHER INFORMATION: Ala or Lys
137 <220> FEATURE:
138 <221> NAME/KEY: MOD_RES
139 <222> LOCATION: (13)
140 <223> OTHER INFORMATION: Ala or Gln
142 <220> FEATURE:
143 <221> NAME/KEY: MOD_RES
144 <222> LOCATION: (14)
145 <223> OTHER INFORMATION: Ala, Leu, Ile, pentylglycine, Val or Met
147 <220> FEATURE:
148 <221> NAME/KEY: MOD_RES
149 <222> LOCATION: (15)...(17)
150 <223> OTHER INFORMATION: Ala or Glu
152 <220> FEATURE:
153 <221> NAME/KEY: MOD_RES
154 <222> LOCATION: (19)
155 <223> OTHER INFORMATION: Ala or Val
157 <220> FEATURE:
158 <221> NAME/KEY: MOD_RES
159 <222> LOCATION: (20)
160 <223> OTHER INFORMATION: Ala or Arg
162 <220> FEATURE:
163 <221> NAME/KEY: MOD_RES
164 <222> LOCATION: (21)
165 <223> OTHER INFORMATION: Ala or Leu
167 <220> FEATURE:
168 <221> NAME/KEY: MOD_RES
169 <222> LOCATION: (22)
170 <223> OTHER INFORMATION: Phe, Tyr or naphthylalanine
172 <220> FEATURE:
173 <221> NAME/KEY: MOD_RES
174 <222> LOCATION: (23)
175 <223> OTHER INFORMATION: Ile, Val, Leu, pentylglycine, tert-butylglycine or Met
177 <220> FEATURE:
178 <221> NAME/KEY: MOD_RES
179 <222> LOCATION: (24)
180 <223> OTHER INFORMATION: Ala, Glu or Asp
182 <220> FEATURE:
183 <221> NAME/KEY: MOD_RES
184 <222> LOCATION: (25)
185 <223> OTHER INFORMATION: Ala, Trp, Phe, Tyr or naphthylalanine
187 <220> FEATURE:
188 <221> NAME/KEY: MOD_RES
189 <222> LOCATION: (26)

RAW SEQUENCE LISTING

DATE: 04/14/2004

PATENT APPLICATION: US/10/656,093B

TIME: 14:39:47

Input Set : A:\256-152div corrected in response to notice to comply.txt

Output Set: N:\CRF4\04142004\J656093B.raw

190 <223> OTHER INFORMATION: Ala or Leu
 192 <220> FEATURE:
 193 <221> NAME/KEY: MOD_RES
 194 <222> LOCATION: (27)
 195 <223> OTHER INFORMATION: Ala or Lys
 197 <220> FEATURE:
 198 <221> NAME/KEY: MOD_RES
 199 <222> LOCATION: (28)
 200 <223> OTHER INFORMATION: Ala or Asn
 202 <220> FEATURE:
 203 <221> NAME/KEY: MOD_RES
 204 <222> LOCATION: (31)
 205 <223> OTHER INFORMATION: Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine
 206 N-alkylpentylglycine or N-alkylalanine
 208 <220> FEATURE:
 209 <221> NAME/KEY: MOD_RES
 210 <222> LOCATION: (36)..(38)
 211 <223> OTHER INFORMATION: Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine
 212 N-alkylpentylglycine or N-alkylalanine
 214 <220> FEATURE:
 215 <221> NAME/KEY: MOD_RES
 216 <222> LOCATION: (39)
 217 <223> OTHER INFORMATION: Ser, Thr, Tyr, Pro, homoproline, 3Hyp, 4Hyp, thioproline,
 218 N-alkylglycine, N-alkylpentylglycine or N-alkylalanine
 220 <220> FEATURE:
 221 <223> OTHER INFORMATION: provided no more than three of Xaa5, Xaa6, Xaa8,
 222 Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17,
 223 Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 or Xaa28
 224 are Ala; and the compound is not exendin-3 or exendin-4
 226 <220> FEATURE:
 227 <223> OTHER INFORMATION: this peptide may encompass 28-39 residues, wherein
 228 residues 1-28 are constant and residues 29-39 may vary
 229 in length according to the specification
 231 <400> SEQUENCE: 4
 W--> 232 Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 233 1 5 10 15
 235 Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 236 20 25 30
 238 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 239 35
 241 <210> SEQ ID NO: 5
 242 <211> LENGTH: 30
 243 <212> TYPE: PRT
 244 <213> ORGANISM: Artificial Sequence
 246 <220> FEATURE:
 247 <223> OTHER INFORMATION: Description of Artificial Sequence: Exendin or
 248 GLP-1 agonist
 250 <220> FEATURE:
 251 <223> OTHER INFORMATION: C-term may be amidated

*what about Xaa's at
 locations 29-30, 32-35?
 (see below)*

RAW SEQUENCE LISTING

DATE: 04/14/2004

PATENT APPLICATION: US/10/656,093B

TIME: 14:39:47

Input Set : A:\256-152div corrected in response to notice to comply.txt

Output Set: N:\CRF4\04142004\J656093B.raw

```

253 <400> SEQUENCE: 5
254 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
255   1           5           10           15
257 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
258           20           25           30
261 <210> SEQ ID NO: 6
262 <211> LENGTH: 28
263 <212> TYPE: PRT
264 <213> ORGANISM: Artificial Sequence
266 <220> FEATURE:
267 <223> OTHER INFORMATION: Description of Artificial Sequence: Exendin or
268     GLP-1 agonist
270 <220> FEATURE:
271 <223> OTHER INFORMATION: C-term amidated
273 <400> SEQUENCE: 6
274 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
275   1           5           10           15
277 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
278           20           25
281 <210> SEQ ID NO: 7
282 <211> LENGTH: 28
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <223> OTHER INFORMATION: Description of Artificial Sequence: Exendin or
288     GLP-1 agonist
290 <220> FEATURE:
291 <223> OTHER INFORMATION: C-term amidated
293 <400> SEQUENCE: 7
294 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu
295   1           5           10           15
297 Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
298           20           25
301 <210> SEQ ID NO: 8
302 <211> LENGTH: 28
303 <212> TYPE: PRT
304 <213> ORGANISM: Artificial Sequence
306 <220> FEATURE:
307 <223> OTHER INFORMATION: Description of Artificial Sequence: Exendin or
308     GLP-1 agonist
310 <220> FEATURE:
311 <223> OTHER INFORMATION: C-term amidated
313 <400> SEQUENCE: 8
314 His Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu
315   1           5           10           15
317 Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
318           20           25
321 <210> SEQ ID NO: 9
322 <211> LENGTH: 28

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/656,093B

DATE: 04/14/2004
TIME: 14:39:48

Input Set : A:\256-152div corrected in response to notice to comply.txt
Output Set: N:\CRF4\04142004\J656093B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24
Seq#:4; Xaa Pos. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
Seq#:47; Xaa Pos. 31, 36, 37, 38
Seq#:48; Xaa Pos. 36, 37, 38
Seq#:49; Xaa Pos. 31
Seq#:50; Xaa Pos. 31, 36, 37
Seq#:51; Xaa Pos. 31, 36, 37
Seq#:52; Xaa Pos. 31, 36
Seq#:55; Xaa Pos. 6
Seq#:59; Xaa Pos. 10
Seq#:60; Xaa Pos. 22
Seq#:61; Xaa Pos. 23
Seq#:65; Xaa Pos. 31, 36, 37
Seq#:66; Xaa Pos. 19
Seq#:67; Xaa Pos. 17
Seq#:75; Xaa Pos. 29

VERIFICATION SUMMARY

DATE: 04/14/2004

PATENT APPLICATION: US/10/656,093B

TIME: 14:39:48

Input Set : A:\256-152div corrected in response to notice to comply.txt

Output Set: N:\CRF4\04142004\J656093B.raw

L:232 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
M:341 Repeated in SeqNo=4
L:1131 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47 after pos.:16
M:341 Repeated in SeqNo=47
L:1162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48 after pos.:32
L:1187 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49 after pos.:16
L:1220 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50 after pos.:16
M:341 Repeated in SeqNo=50
L:1253 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51 after pos.:16
M:341 Repeated in SeqNo=51
L:1286 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:52 after pos.:16
M:341 Repeated in SeqNo=52
L:1354 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55 after pos.:0
L:1439 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59 after pos.:0
L:1467 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60 after pos.:16
L:1492 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61 after pos.:16
L:1585 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65 after pos.:16
M:341 Repeated in SeqNo=65
L:1635 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66 after pos.:16
L:1642 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:67
L:1673 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67 after pos.:16
L:1878 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75 after pos.:16